1 / 18

HIV-2: Background

Development of an HIV-2 RNA International Standard Harvey Holmes, Clare Morris, Neil Berry, Alan Heath and Collaborative Study Group. HIV-2: Background. HIV-2 is a diverse group of viruses closely related to and thought to be derived from the SIV of sooty mangabey monkeys

alvin-wyatt
Download Presentation

HIV-2: Background

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Development of an HIV-2 RNA International StandardHarvey Holmes, Clare Morris, Neil Berry, Alan Heath and Collaborative Study Group

  2. HIV-2: Background • HIV-2 is a diverse group of viruses closely related to and thought to be derived from the SIV of sooty mangabey monkeys • First isolated in 1986 from AIDS patient in West Africa • Generally confined to W Africa and in countries with close links such as Portugal. • Different subtypes exist; A and B main subtypes infecting humans • Different disease progression to HIV-1 • Lower virulence – slower progression to AIDS • Lower viral load – lower transmission rates • Poorly or not detected by most HIV-1 assays. • International Standard for HIV-2 RNA would be valuable for assays that detect HIV-2

  3. HIV-2 Virus Isolates • Genotype A most common HIV-2 subtype affecting humans • Although most subtype A strains have been grown in culture, subtype B strains less easily cultured • In consultation with WHO and CBER/FDA, two subtype A strains were identified that were available and for which full length sequences had been published: • HIV-2 ROD – isolated 1985 in Cape Verde Islands, Senegal • HIV-2 CAM2 – isolated 1987 in Guinea Bissau • Low passage isolates acquired that grew well in T-cell lines

  4. HIV2 ALI HIV2 MD2 HIV2 BEN HIV2 CAM HIV2 GH1 NIBSC CAM-2 HIV2 D194 HIV1 ISY HIV2 UC2 HIV2 MCR35 HIV2 MCN13 HIV2 ROD SIV MMH4 NIBSC HIV-2 ROD SIV 32H SIV 239 SIV 251 1A11 HIV2 D205 HIV2 UC1 HIV2 KR020 HIV2 EHO HIV-2 7312A 0.02 HIV-2 gag sequences HIV-2 subtype A SIVmac/smm HIV-2 subtype B SoGAT XXI

  5. Preparation of candidate standards • Virus cultured in CEM cells and stocks stored down at ≤ -80oC • RNA concentration determined using in house real time PCR assay (LTR) • Virus heat inactivated at 600C for 60 minutes • Inactivation confirmed using tissue culture • No growth with inactivated samples • 2500 vials of each virus freeze dried

  6. RNA concentration • Virus stocks tested pre and post heat inactivation and pre and post freeze drying NIBSC real-time PCR assay - values shown as copy number (log10)

  7. International Collaborative Study • 29 laboratories took part in the collaborative study. • Including Europe, USA, Canada, Japan, Australia, South Africa • Each Lab was sent 4 vials of each of candidate labelled S1-S4 • S1 and S2 were HIV-2 CAM2 • S3 and S4 were HIV-2 ROD • Requested to test in at least 3 assays, with the first assay containing 10 fold dilutions, then 0.5 log dilution around the end point • Majority of results were from qualitative assays – from which end-point dilutions were determined • 9 labs provided quantitative data from in-house assays • Quantitative estimates used where all results positive or limited range of dilutions used • Both quantitative and qualitative estimates used where full set of set of dilutions across end-point provided • Results analysed by NIBSC statistician (Alan Heath)

  8. HIV-2 CAM2 HIV-2 CAM2 SoGAT XXI

  9. HIV-2 ROD HIV-2 ROD SoGAT XXI

  10. HIV-2 CAM2 HIV-2 CAM2 SoGAT XXI

  11. HIV-2 ROD HIV-2 ROD SoGAT XXI

  12. (CAM2 relative to CAM2) SoGAT XXI

  13. (ROD relative to CAM2) SoGAT XXI

  14. (ROD relative to CAM2) SoGAT XXI

  15. Stability - Accelerated Degradation Studies • Vials of freeze dried CAM-2 and ROD stored at range of elevated temperatures • Tested at intervals of 4, 8, 12 months, 2,3,4,5 years • Can predict stability using Arrhenius equation

  16. Conclusions and proposal • Considerable variation between the results from different labs and different assays • Use of relative potency improves agreement between labs and assay methods • Good agreement between S1 and S2 (HIV-2 CAM2) and between S3 and S4 (HIV-2 ROD) • Statistically, results were similar and there was no preference for either S1/S2 or S3/S4 • We suggest that HIV-2 CAM2 (S1/S2) be proposed to WHO ECBS as 1st International Standard for HIV-2 RNA with a unitage of 10,000 IU/vial/ml • We welcome feedback and comments from the SoGAT Working Group

  17. Acknowledgements • NIBSC Project Team • Dr. Indira Hewlett, CBER/FDA, USA • Dr Ana Padilla, WHO, Switzerland • Collaborative Study Group • 29 international participants – Thank You !!!!!

  18. Other HIV-1 Standards Current HIV-1 2nd IS has stocks that will last 3-4 years Need to start planning replacement now Virus HIV-1 genotype B stock used for previous IS still available – shall we use this?? Should we heat-inactivate the virus? This makes processing and shipping more straight-forward 2nd genotype panel – work is underway Collaborative study: 2010

More Related